PTC Therapeutics, Inc. (PTCT) Stock Price

PTCTStock
$73.47+40.52%52W
Market Cap$6.13B
P/E8.80x
PEG Ratio
Div yield
Beta0.48

PTCT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-8.16%
Price vs S&P 500 (4W)-8.80%
VGM Score48.79
P/E Ratio (Annual)8.80x

PTCT Earnings Surprise History

Q2 25-0.83est. -1.06
Q3 250.19est. -1.11
Q4 25-1.80est. -0.41
Q1 26-0.03est. -0.44
Q2 260.92est. 0.34

PTCT Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.82
3.95
4.05
4.05

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
PTCTPTC Therapeutics, Inc.
DBC$73.47
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About PTC Therapeutics, Inc.

PTC Therapeutics develops and commercializes medicines for rare genetic and metabolic disorders, with a focus on neurology. The company markets several FDA-approved therapies and maintains a pipeline of clinical and preclinical candidates for pediatric and adult patients. Its diversified portfolio addresses significant unmet needs in rare disease treatment.